The US FDA’s Dr. Harpreet Singh talks with ILCN about what the increasing use of AI means for the agency as it works to ensure drugs and devices are safe and effective. Read more
In light of data from FLAURA2 and MARIPOSA, Drs. Suresh Ramalingam and Joshua Sabari weighed the pros and cons during the 2024 TTLC meeting. Read more
During a recent debate, Drs. Anne Chiang and Stephen Liu offered differing perspectives on the feasibility of biomarker use in the small-cell lung cancer space. Read more
The move was supported by preliminary evidence from a phase I, first-in-human study in patients with advanced NSCLC. Read more
Lung Cancer 360 offers a centralized hub for thoracic oncology learning opportunities spanning multiple disciplines and formats. Read more
In an interview with ILCN, Dr. Carolyn Presley discusses combating malnourishment in vulnerable populations and the role of the microbiome in immunotherapy efficacy. Read more
Surgeon Erin Gillaspie, MD, said surgery still has a role in the treatment of mesothelioma while medical oncologist Hedy Kindler, MD, said newer systemic therapies make surgery obsolete in this space. Read more
Dr. Mark Kris, who leads the IASLC Pathologic Response Project, recently provided an update on efforts to collect data to confirm whether pathologic complete response can predict long-term outcomes. Read more
Advocate Angus Pratt explores the issues patients face while researching their disease when inaccurate and out-of-date information is everywhere. Read more
The agency also granted approval to amivantamab as a treatment for patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations who progressed on or after platinum-based chemotherapy. Read more